[
    [
        {
            "time": "2023-10-18",
            "original_text": "公告精选丨中芯国际成科创板摘“U”第一股，17连板顺控发展回复关注函",
            "features": {
                "keywords": [
                    "中芯国际",
                    "科创板",
                    "摘U",
                    "顺控发展",
                    "连板"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "半导体",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "公告精选丨中芯国际成科创板摘“U”第一股，17连板顺控发展回复关注函",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "晚间重要公告汇总",
            "features": {
                "keywords": [
                    "晚间公告",
                    "汇总"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "晚间重要公告汇总",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "[公司]华东医药全球首创ADC新药获批临床 有望填补卵巢癌治疗空白",
            "features": {
                "keywords": [
                    "华东医药",
                    "ADC新药",
                    "临床试验",
                    "卵巢癌"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[公司]华东医药全球首创ADC新药获批临床 有望填补卵巢癌治疗空白",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "华东医药：新药临床试验申请获得批准",
            "features": {
                "keywords": [
                    "华东医药",
                    "新药",
                    "临床试验",
                    "批准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：新药临床试验申请获得批准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "华东医药(000963.SZ)：生物制品1类新药IMGN853临床试验申请获批",
            "features": {
                "keywords": [
                    "华东医药",
                    "IMGN853",
                    "生物制品",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)：生物制品1类新药IMGN853临床试验申请获批",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "华东医药(000963.SZ)子公司获药物临床试验批准通知书",
            "features": {
                "keywords": [
                    "华东医药",
                    "子公司",
                    "药物",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)子公司获药物临床试验批准通知书",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "请问少女针审批是不是遇到了麻烦？华东医药：英国全资子公司新型胶原蛋白刺激剂Ellansé?正在等待中国上市的注册审批",
            "features": {
                "keywords": [
                    "华东医药",
                    "少女针",
                    "Ellansé",
                    "注册审批"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "美容"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "请问少女针审批是不是遇到了麻烦？华东医药：英国全资子公司新型胶原蛋白刺激剂Ellansé?正在等待中国上市的注册审批",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "华东医药：恩格列净二甲双胍复方片（5/500mg）已申报生产",
            "features": {
                "keywords": [
                    "华东医药",
                    "恩格列净",
                    "二甲双胍",
                    "复方片",
                    "申报生产"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：恩格列净二甲双胍复方片（5/500mg）已申报生产",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "华东医药引进的叶酸受体α靶向ADC获批临床｜医麦猛爆料",
            "features": {
                "keywords": [
                    "华东医药",
                    "叶酸受体",
                    "ADC",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药引进的叶酸受体α靶向ADC获批临床｜医麦猛爆料",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "华东医药1类生物制药IMGN853获批临床",
            "features": {
                "keywords": [
                    "华东医药",
                    "IMGN853",
                    "生物制药",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药1类生物制药IMGN853获批临床",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "融资客青睐6股，奥来德买入占比高达56.26%",
            "features": {
                "keywords": [
                    "融资客",
                    "奥来德",
                    "买入占比"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "材料"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "融资客青睐6股，奥来德买入占比高达56.26%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]